References
1. Dhodapkar MV. MGUS to myeloma: a mysterious gammopathy of underexplored significance. Blood. 2016;128(23):2599-2606. doi:10.1182/blood-2016-09-692954
2. van Nieuwenhuijzen N, Spaan I, Raymakers R, et al. From MGUS to multiple myeloma, a paradigm for clonal evolution of premalignant cells. Cancer Res. 2018;78(10):2449-2456. doi:10.1158/0008-5472.CAN-17-3115
3. Survival rate by stage for multiple myeloma. American Cancer Society. Reviewed January 21, 2021. Accessed June 25, 2021. https://www.cancer.org/cancer/multiple-myeloma/detection-diagnosis-staging/survival-rates.html
4. Ho M, Patel A, Goh CY, et al. Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). Leukemia. 2020;34(12):3111-3125. doi:10.1038/s41375-020-01051-x
5. Atkin C, Richter A, Sapey E. What is the significance of monoclonal gammopathy of undetermined significance? Clin Med (Lond). 2018;18(5):391-396. doi:10.7861/clinmedicine.18-5-391
6. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Multiple Myeloma. Version 7.2021. April 26, 2021. https://www.nccn.org
7. Key statistics about multiple myeloma. American Cancer Society. Revised January 12, 2021. Accessed June 25, 2021. https://www.cancer.org/cancer/multiple-myeloma/about/key-statistics.html
8. Risk factors for multiple myeloma. American Cancer Society. Revised February 28, 2018. Accessed July 14, 2021. https://www.cancer.org/cancer/multiple-myeloma/causes-risks-prevention/risk-factors.html
9. Medical Masterclass contributors, Firth J. Haematology: multiple myeloma. Clin Med (Lond). 2019;19(1):58-60. doi:10.7861/clinmedicine.19-1-58
10. Walker BA, Mavrommatis K, Wardell CP, et al. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood. 2018;132(6):587-597. doi:10.1182/blood-2018-03-840132
11. Mateos MV, Landgren O. MGUS and smoldering multiple myeloma: diagnosis and epidemiology. Cancer Treat Res. 2016;169:3-12. doi:10.1007/978-3-319-40320-5_1
12. Kyle RA, Durie BG, Rajkumar SV, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia. 2010;24(6):1121-1127. doi:10.1038/leu.2010.60
13. Landgren O, Hofmann JN, McShane CM, et al. Association of immune marker changes with progression of monoclonal gammopathy of undetermined significance to multiple myeloma. JAMA Oncol. 2019;5(9):1293-1301. doi:10.1001/jamaoncol.2019.1568
14. Rajkumar SV, Kumar S. Multiple myeloma current treatment algorithms. Blood Cancer J. 2020;10(9):94. doi:10.1038/s41408-020-00359-2
15. Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538-e548. doi:10.1016/S1470-2045(14)70442-5
16. Morrison T, Booth RA, Hauff K, et al. Laboratory assessment of multiple myeloma. Adv Clin Chem. 2019;89:1-58. doi:10.1016/bs.acc.2018.12.001
17. Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33(26):2863-2869. doi:10.1200/JCO.2015.61.2267
18. Pawlyn C, Davies FE. Toward personalized treatment in multiple myeloma based on molecular characteristics. Blood. 2019;133(7):660-675. doi:10.1182/blood-2018-09-825331
Models used for illustrative purposes only.
Published date: Aug 2021